BioBusiness

New reports indicate that drug prices are slowing compared to other healthcare costs.

The 2017 Global Healthcare Leaders Survey suggests that value-based and risk-sharing payment could have an even more transformative impact on the industry than scientific breakthroughs.

In Lazard's Global Healthcare Leaders 2017 survey, most respondents said pricing and reimbursement were the most significant challenge, but nearly half of the pharma executives who responded see value-based pricing as having the greatest impact on the business, potentially even more than scientific breakthroughs.

Biomedical researcher shares insights from a career dedicated to advancing therapeutic innovations for unmet medical needs.

Pharmaceutical companies need to radically change to survive and thrive amid shifting healthcare and technology changes.

New study shows China biopharma companies face staffing shortages.

Philadelphia plays host to the exhibits, conferences, and networking activities of CPhI North America on May 16-18, 2017.

An influx of millennial workers may have an impact on whether pharma manufacturers choose to implement IIoT technology.

A controversial naming convention attempts to explain important distinctions between biologic drugs and their biosimilar counterparts.

Pharmaceutical Technology spoke with Tommy Fanning, head of biopharmaceuticals for IDA Ireland, to get a perspective on how Brexit may affect the pharmaceutical industry.

Reducing regulatory roadblocks requires more than the stroke of a pen.

Report: Global medicine spending will reach nearly $1.5 trillion by 2021.

Questions about new healthcare policies, investments, drug approvals, and more will test Biopharma.

What will manufacturers have to do to ensure the continued uptake of biosimilars?

Rookie API developers beat pharma at its own game.

Job security may have increased, but biopharma professionals remain somewhat dissatisfied with pay levels.

What’s ahead for the healthcare and pharmaceutical industries?

Value assessment initiatives are expected to have a major impact on drug use and reimbursement.

Steep price increases for a popular drug have created patient and Congressional backlash.

A KPMG survey reveals that approximately 84% of pharma and medical device executives plan to add jobs in next 12 months.

Congressional partisanship creates noise, but no funding for Zika virus research.

CPhI Pharma Awards seek nominations for excellence in biopharma development and manufacturing.

Contract service providers debate the pros and cons of consolidation, accelerated drug approvals, regulatory issues, and the impact of new therapies.

New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China.

Biopharmaceutical contractors continue to invest in development, facility upgrades, technological advancement, and mergers and acquisitions.